

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### Atogepant for treating migraine [ID6615]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Consultation responses highlighted that the prevalence of migraines is higher in women. The 2016 Global Burden of Disease Study estimated that 24% of women in the UK are living with migraine or probable migraine compared to 12% of men.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Committee will consider the impact of this during the appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Updated prevalence including global disability impact for women now included in scope.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders identified.

**Approved by Principal Technical Adviser (name):** Elizabeth Bell

**Date:** 10/12/2025